• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

    127.56 -0.48 (-0.37%)
    Streaming Delayed Price Updated: 1:20 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 238,499
    Open 129.18
    Bid (Size) 127.39 (100)
    Ask (Size) 127.72 (200)
    Prev. Close 128.04
    Today's Range 127.22 - 130.41
    52wk Range 104.73 - 160.18
    Shares Outstanding 100,100,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup ↗
    Via Chartmill

    Performance

    YTD
    -9.3%
    -9.3%
    1 Month
    -0.9%
    -0.9%
    3 Month
    -5.2%
    -5.2%
    6 Month
    -14.4%
    -14.4%
    1 Year
    +19.8%
    +19.8%

    More News

    Read More
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗
    Via Chartmill
    Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price ↗
    Via Chartmill
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation ↗
    Via Chartmill
    Wall Street Holds Its Ground While Trump's Iran Deadline Ticks Down ↗
    Via Chartmill
    Topics Government
    News headline image
    Why Soleno Therapeutics Stock Rocketed Higher on Monday ↗
    Via The Motley Fool
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Via MarketMinute
    Topics Intellectual Property
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗
    Via Chartmill
    News headline image
    Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
    Via The Motley Fool
    News headline image
    CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
    Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
    Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
    The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
    What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
    The current price of Neurocrine Biosciences, Inc. - Common Stock is 127.56
    When was Neurocrine Biosciences, Inc. - Common Stock last traded?
    The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 04/28/26 01:20 PM ET
    What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
    The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 12.77B
    How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
    Neurocrine Biosciences, Inc. - Common Stock has 13B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.